INVA Innoviva Inc.

13.78
+0.29  (2%)
Previous Close 13.49
Open 13.47
Price To book -5.09
Market Cap 1506991052
Shares 109,360,744
Volume 344,385
Short Ratio 9.56
Av. Daily Volume 1,065,568

SEC filingsSee all SEC filings

  1. 8-K - Current report 171093261
  2. 8-K - Current report 171090734
  3. 8-K - Current report 171086820
  4. 8-K - Current report 171042119
  5. 144 - Report of proposed sale of securities 171020811

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced September 18, 2017.
FF/UMEC/VI
Chronic obstructive pulmonary disease (COPD)
Phase 3 data due 2H 2018.
Closed Triple
Asthma

Latest News

  1. Innoviva to Participate in Cantor Fitzgerald’s Global Healthcare Conference on September 26
  2. Glaxo-Innoviva's Triple Combo Inhaler Positive in Phase III
  3. GSK and Innoviva Report Positive Headline Results from IMPACT Study Showing Single Inhaler Triple Therapy Trelegy Ellipta Reduced COPD Exacerbations
  4. FDA OKs Glaxo's inhaler, first one to combine 3 medicines
  5. Glaxo/Innoviva's Triple Combo Therapy Gets FDA Nod for COPD
  6. Trelegy Ellipta approved as the first once-daily single inhaler triple therapy for the treatment of appropriate patients with COPD in the US
  7. Trelegy Ellipta Approved as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Appropriate Patients with COPD in the US
  8. Glaxo's Triple Therapy COPD Inhaler Gets CHMP Nod in the EU
  9. Trelegy Ellipta Once-Daily Single Inhaler Triple Therapy Receives Positive Opinion from the CHMP in Europe for Appropriate Patients with COPD
  10. See what the IHS Markit Score report has to say about Innoviva Inc.
  11. Positive Results from Pioneering Salford Lung Study in Asthma Published in The Lancet, and Presented at European Respiratory Congress
  12. Innoviva to Participate in Morgan Stanley’s Global Healthcare Unplugged Conference on September 12
  13. Innoviva to Participate in Baird Global Healthcare Conference on September 7
  14. Stocks Showing Improving Market Leadership: Innoviva Earns 84 RS Rating
  15. Innoviva, Inc. breached its 50 day moving average in a Bullish Manner : INVA-US : August 28, 2017
  16. Innoviva, Inc. – Value Analysis (NASDAQ:INVA) : August 21, 2017
  17. Innoviva Completes Refinancing of its 9% 2029 Non-Recourse Notes

SEC Filings

  1. 8-K - Current report 171093261
  2. 8-K - Current report 171090734
  3. 8-K - Current report 171086820
  4. 8-K - Current report 171042119
  5. 144 - Report of proposed sale of securities 171020811
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015368
  7. 8-K - Current report 171012141
  8. 8-K - Current report 17998201
  9. 8-K - Current report 17994121
  10. 8-K - Current report 17982974